Valeritas

51 articles about Valeritas

• Valeritas Wins Silver Medal And Announces Positive Results Of Two Retrospective Study Analyses Of The V-Go Disposable Insulin Delivery Device In Poster Presentations At AMCP

  4/22/2016

• Rodney D. Altman, MD Joins Valeritas Board Of Directors

  4/19/2016

• Valeritas Officially Shelves $75 MIllion IPO

  3/11/2016

• Insulin Delivery With Valeritas' V-Go Disposable Insulin Delivery Device Demonstrated Greater Glycemic Control, Less Insulin Utilization And Cost Effectiveness When Compared To Subcutaneous Multiple Daily Insulin Injections

  2/16/2016

• Valeritas’ V-Go Device Shows To Help Improve Compliance And Efficacy For Patients With Diabetes On Insulin + GLP-1 Therapy As Well As Those Who Switched From Subcutaneous Insulin Injections To V-Go

  10/23/2015

• Valeritas’ V-Go Disposable Insulin Delivery Device Demonstrates Efficacy And Safety In Patients With Diabetes

  10/22/2015

• Real-World Study Data Demonstrating That Valeritas' V-Go Consistently Reduces A1C Levels And Decreases Insulin Requirements For Patients With Diabetes Regardless Of Baseline A1C Presented At American Diabetes Association 2015

  6/8/2015

• Study Shows That Valeritas' V-Go Improves Blood Glucose Control And Reduces Insulin Requirements In Residents Of Long Term Care Facilities

  5/18/2015

• Real-World Data From Three Separate Studies Demonstrate That Valeritas' V-Go Significantly Reduces A1c And Lowers Total Daily Insulin Dose For Patients With Diabetes

  5/18/2015

• Study Analysis Shows Valeritas' V-Go Device Helps Reduce Diabetes Management Cost For Type 2 Diabetes Patients By Improving Glycemic Control And Reducing Insulin Doses

  4/10/2015

• Insulin Delivery Device Maker Valeritas Postpones $75 Million IPO

  3/26/2015

• Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award

  10/20/2014

• Type 2 Insulin Pump Maker Valeritas Eyes $45 Million

  7/9/2014

• Interim Analysis Suggests That Delivery Of Insulin Via Valeritas' V-Go® Shows Promise In Improving Glycemic Control For Patients With Type 2 Diabetes Previously Taking Long-Acting Insulin

  5/16/2014

• Valeritas Raises $100 Million

  6/4/2013

• New Interim Analysis From Observational Study Suggests That Delivery of Insulin Via Valeritas' V-Go Shows Promise in Improving Glycemic Control for Patients With Type 2 Diabetes

  5/3/2013

• Valeritas Selects dLife's New Diabetes Patient Engagement Solution for Valeritas' V-go Disposable Insulin Delivery Device

  5/22/2012

• Valeritas Replaces Complicated Client/Server CRM with Intuitive Veeva Systems, Inc. CRM in the Cloud

  4/25/2012

• Valeritas Announces $150 Million Financing

  9/13/2011

• Valeritas Receives European CE Mark Approval for the V-Go(TM) Disposable Insulin Delivery Device

  7/25/2011